CD52 Inhibitors
2 drugsAbout CD52
CD52 is a glycoprotein highly expressed on lymphocytes, making it a target for immunosuppressive therapies. While its precise function is still being researched, its abundance on immune cells makes it an attractive target.
CD52 has clinical viability in autoimmune diseases and certain cancers, but there is currently no genetic evidence directly linking CD52 to specific diseases.
CD52 is targeted by two FDA-approved antibody drugs, LEMTRADA and CAMPATH, both marketed by Sanofi, for CNS and other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Graft Failure with only 1 trials.
- phase3 represents biological uncertainty with 33% completion.
Top Drugs
Sanofi is the only company with approved drugs targeting CD52.
High market concentration suggests high entry barriers or limited commercial opportunity.
Drug Modality Landscape
Modalities
Routes of Administration
CD52 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Explore alternative modalities like small molecules to differentiate from existing therapies.
Clinical Trials 122 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 43 | 22 | 7 | 14 | 76% |
| Phase 2 | 58 | 20 | 16 | 20 | 56% |
| Phase 3 | 10 | 6 | 2 | 2 | 75% |
| Phase 4 | 11 | 9 | 2 | 0 | 82% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2001 - 2001)
The first CD52-targeting drug was approved in 2001, with the most recent approval in the same year.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new CD52-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 52 clinical trials targeting CD52.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities